Literature DB >> 30003753

MiR-384 represses tumorigenesis by regulating CDK6 and predicts prognosis of clear cell renal cell carcinoma.

Lihua Guo1, Dayu Wang, Zhiping Zhang.   

Abstract

PURPOSE: Clear cell renal cell carcinoma (ccRCC) accounts for 70-80% of renal cell carcinomas. Various microRNAs (miRs) have been reported to affect the tumorigenesis of ccRCC. However, the role of miR-384 in ccRCC is still unknown. Thus, the purpose of this study was to investigate the function of miR-384 in ccRCC.
METHODS: qRT-PCR or Western blot were employed to examine the expressions of miR-384 and CDK6 in ccRCC tissues or cell lines. MTT and transwell assays were applied to measure cell proliferation and motility. The survival rate was analyzed by Kaplan-Meier method accompanied with log-rank test. Dual luciferase assay was used to verify the relationship among miR-384 and CDK6 in ccRCC cells.
RESULTS: MiR-384 was downregulated in ccRCC tissues and cell lines, and its overexpression inhibited cell proliferation and motility in ccRCC. In addition, miR-384 was found to be a marker for good prognosis in ccRCC. Furthermore, CDK6 was confirmed to be directly targeted by miR-384, and upregulation of CDK6 restored the inhibitory effects of miR- 384 in ccRCC.
CONCLUSION: MiR-384 repressed tumorigenesis by regulating CDK6 in ccRCC and predicted good prognosis for ccRCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30003753

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  2 in total

1.  FTO modifies the m6A level of MALAT and promotes bladder cancer progression.

Authors:  Le Tao; Xingyu Mu; Haige Chen; Di Jin; Ruiyun Zhang; Yuyang Zhao; Jie Fan; Ming Cao; Zhihua Zhou
Journal:  Clin Transl Med       Date:  2021-02

2.  The prognostic value of miRNA-18a-5p in clear cell renal cell carcinoma and its function via the miRNA-18a-5p/HIF1A/PVT1 pathway.

Authors:  Huan Wang; Zhong-Yi Li; Zu-Hao Xu; Yuan-Lei Chen; Ze-Yi Lu; Dan-Yang Shen; Jie-Yang Lu; Qi-Ming Zheng; Li-Ya Wang; Li-Wei Xu; Ding-Wei Xue; Hai-Yang Wu; Li-Qun Xia; Gong-Hui Li
Journal:  J Cancer       Date:  2020-02-20       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.